The U.S. Food and Drug Administration set a Feb. 25, 2011, target to decide whether to approve Protalix BioTherapeutics Inc.'s (PLX) drug for a rare genetic disease, later than the Israeli biopharmaceutical company expected last monthThe treatment, taligulucerase alfa, is being developed for Gauch

read more>>

CARMIEL, Israel -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that the French regulatory authority has granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher diseaseAn ATU is the regulator

read more>>

CARMIEL, Israel -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDAThe FDA granted taliglucerase alfa a standard review time of ten months

read more>>

Biopharmaceutical company, Shire plc (SHPGY: News ), Thursday said its open label Phase I/II study named TKT-025 EXT for VPRIV, an enzyme replacement therapy for patients with type 1 Gaucher disease, provided positive resultsThe data was presented at the 9th Annual European Working Group on Gauc

read more>>

LONDON -- The European Medicines Agency Friday recommended marketing authorization be granted to Shire PLC's (SHP.LN) Vpriv, a drug developed to treat a rare genetic condition called Gaucher diseaseThe agency's Committee for Medicinal Products for Human Use recommended approval following an accele

read more>>

Shire plc , the global specialty biopharmaceutical company, today announced the availability of the OnePath(SM) Gaucher Application (appThe first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Applic

read more>>

CAMBRIDGE, Massachusetts -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received the 2010 Partners in Progress Corporate Award from NORDShire was recognized for its efforts to accelerate the development of VPRIV(TM), a human cell

read more>>

WASHINGTON -- The National Organization for Rare Disorders (NORD) will honor two trailblazing scientists, a pioneering patient organization, and five companies that have brought innovative new treatments to market for rare diseases at the 2010 NORD Partners in Progress Gala at the Andrew W. Mellon

read more>>

LA JOLLA, CA  --  In findings that advance scientists' understanding of a whole class of inherited disorders, a team from The Scripps Research Institute has shed light on a mechanism that enables a potential treatment for Gaucher's disease and other lysosomal storage diseasesThe findings

read more>>

Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patientsIn a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglust

read more>>